Related Experiment Video
Updated: Jul 5, 2026
Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
Published on: October 17, 2025
Biologic features and treatment outcome of secondary acute lymphoblastic leukemia--a review of 101 cases
R Shivakumar1, W Tan, G E Wilding
1Leukemia Section, Department of Medicine, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA.
Background:
Secondary acute lymphoblastic leukemia (sALL) is a rare disease and its biologic features are not well characterized.
Patients And Methods:
We describe a cohort of seven patients and discuss 94 additional cases from the literature for whom biological parameters were described. Cases with incomplete data were excluded.
Results:
Hodgkin's disease (HD) was more common in the 18-59 age group while breast and prostate cancers were prevalent only in the >or=18-year-old patients. The time interval to develop sALL was similar among all age groups but was significantly longer for HD and neuroblastoma primary diagnoses and sALL with complex karyotype. T-cell immunophenotype was more common in the <18 age group. Complete remission was infrequent in the >or=60 age group. The overall survival was poor for all sALL regardless of age, primary diagnoses, cytogenetic subgroups, or immunophenotype. Allogeneic transplantation most probably represents the only chance of cure.
Conclusion:
Better identification of prognostic factors to prevent the occurrence of sALL is indicated.